StemCells, Inc. Transplants First Patient in Phase II Clinical Trial for Dry Age-Related Macular Degeneration 
Radiant(TM) Study is the First Controlled Phase II Trial to Investigate the Efficacy of Human Neural Stem Cells for the Treatment of Dry AMD
NEWARK, Calif., July 20, 2015 (GLOBE NEWSWIRE) — StemCells, Inc. a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the brain, eye and spine, announced today that it has completed transplantation of the first subject in its Radiant Study at the Retina Foundation of the Southwest. The Phase II trial is designed to evaluate both the safety and efficacy of the Company’s proprietary HuCNS-SC® platform technology (purified human neural stem cells) for the treatment of geographic atrophy (GA), the most advanced form of dry age-related macular degeneration (AMD).
“Initiation of this fellow eye controlled Phase II clinical trial re-affirms our leadership in the study of stem cells to treat disorders of the eye,” said Joel Naor, M.D., MSc, MBA, Vice President of Ophthalmology Clinical Development, at StemCells, Inc. “AMD is a debilitating condition that severely impacts quality of life for millions of people and for which there is currently no treatment. HuCNS-SC cells may have the potential to preserve vision in those affected with dry AMD and possibly other degenerative retinal disorders.”
About Age-Related Macular Degeneration
Age-related macular degeneration refers to a loss of photoreceptors (rods and cones) from the macula, the central part of the retina. AMD typically manifests in adults in their 50s or early 60s and gradually progresses to compromise central vision. With an estimated 25-30 million cases worldwide, AMD is the number one cause of severe vision loss and legal blindness in adults over the age of 55…….
See more at: http://globenewswire.com/news-release/2015/07/20/753408/10142035/en/StemCells-Inc-Transplants-First-Patient-in-Phase-II-Clinical-Trial-for-Dry-Age-Related-Macular-Degeneration.html#sthash.m54Xb9Mk.dpuf
Source: Globe Newswire

On